Role of the N-Acetylation Polymorphism in Solithromycin Metabolism

References

• Global Burden of Disease Study 2013 Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet386 ( 9995 ), 743 – 800 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zhanel GG , HartelE , AdamHet al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial pneumonia . Drugs76 ( 18 ), 1737 – 1757 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barrera CM , MykietiukA , MetevHet al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL) . Lancet Infect. Dis.16 ( 4 ), 421 – 430 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Jamieson BD , CiricS , FernandesP . Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment . Antimicrob. Agents Chemother.59 ( 8 ), 4379 – 4386 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Furfaro LL , SpillerOB , KeelanJA , PayneMS . In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin . Int. J. Antimicrob. Agents46 ( 3 ), 319 – 324 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ekstedt M , HagstromH , NasrPet al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up . Hepatology61 ( 5 ), 1547 – 1554 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rotman Y , SanyalAJ . Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease . Gut66 ( 1 ), 180 – 190 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Musso G , De MichieliF , BongiovanniDet al. New pharmacologic agents that target inflammation and fibrosis in nonalcoholic steatohepatitis-related kidney disease . Clin. Gastroenterol. Hepatol. doi:10.1016/j.cgh.2016.08.002 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Hein DW . N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine . Expert Opin. Drug Metab. Toxicol.5 ( 4 ), 353 – 366 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Weber WW , HeinDW . N-acetylation pharmacogenetics . Pharmacol. Rev.37 ( 1 ), 25 – 79 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• McDonagh EM , BoukouvalaS , AklilluE , HeinDW , AltmanRB , KleinTE . PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 . Pharmacogenet. Genomics24 ( 8 ), 409 – 425 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fretland AJ , DollMA , LeffMA , HeinDW . Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1 . Pharmacogenetics11 ( 6 ), 511 – 520 ( 2001 ).
   PubMedGoogle Scholar
• Fretland AJ , LeffMA , DollMA , HeinDW . Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms . Pharmacogenetics11 ( 3 ), 207 – 215 ( 2001 ).
   PubMedGoogle Scholar
• Gomez-Lechon MJ , DonatoMT , CastellJV , JoverR . Human hepatocytes as a tool for studying toxicity and drug metabolism . Curr. Drug Metab.4 ( 4 ), 292 – 312 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Doll MA , ZangY , MoellerT , HeinDW . Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes . J. Pharmacol. Exp. Ther.334 ( 2 ), 540 – 544 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hein DW , DollMA . Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes . Pharmacogenomics13 ( 1 ), 31 – 41 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Doll MA , Salazar-GonzálezRA , HeinDW . Acetylator genotype-dependent N-acetylation of isoniazid in human hepatocytes in situ . Presented at : The Sixth International Workshop on Arylamine N-acetyltransferases . Toronto, Canada , 4–6 October 2013 .
   Google Scholar
• Leff MA , FretlandAJ , DollMA , HeinDW . Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype . J. Biol. Chem.274 ( 49 ), 34519 – 34522 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Doll MA , HeinDW . Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes . Anal. Biochem.288 ( 1 ), 106 – 108 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hein DW , FergusonRJ , DollMA , RustanTD , GrayK . Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes . Hum. Mol. Genet.3 ( 5 ), 729 – 734 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Hein DW , DollMA , RustanTD , FergusonRJ . Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions . Cancer Res.55 ( 16 ), 3531 – 3536 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Grant DM , HughesNC , JanezicSAet al. Human acetyltransferase polymorphisms . Mutat. Res.376 ( 1–2 ), 61 – 70 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Hickman D , PalamandaJR , UnadkatJD , SimE . Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli . Biochem. Pharmacol.50 ( 5 ), 697 – 703 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Evans DA , ManleyKA , McKusickV . Genetic control of isoniazid metabolism in man . Br. Med. J.2 ( 5197 ), 485 – 491 ( 1960 ).
   PubMed Web of Science ®Google Scholar
• Donald PR , SirgelFA , VenterAet al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid . Clin. Infect. Dis.39 ( 10 ), 1425 – 1430 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG , SrivastavaS , GumboT . Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy . Clin. Infect. Dis.55 ( 2 ), 169 – 177 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers M , Tomalik-ScharteD , JetterAet al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49 ( 5 ), 1733 – 1738 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zabost A , BrzezinskaS , KozinskaMet al. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients . BioMed Res. Int. 2013 , 853602 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Matsumoto T , OhnoM , AzumaJ . Future of pharmacogenetics-based therapy for tuberculosis . Pharmacogenomics15 ( 5 ), 601 – 607 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jung JA , KimTE , LeeHet al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis . Drug Des. Devel. Ther.9 , 5433 – 5438 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Choi R , JeongBH , KohWJ , LeeSY . Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations . Ann. Lab. Med.37 ( 2 ), 97 – 107 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Azuma J , OhnoM , KubotaRet al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy . Eur. J. Clin. Pharmacol.69 ( 5 ), 1091 – 1101 ( 2013 ).
   PubMed Web of Science ®Google Scholar